{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"55"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"70"}],"units":"Participants"}],"description":"OS assessed by number of participants alive at the end of follow up period.","groups":[{"description":"Patients receive activated Marrow Infiltrating Lymphocytes (aMIL)\n\naMIL: On day 0, patients will receive auto transplant followed by Tadalafil and aMIL. At day 60, patients will receive Lenalidomide.","id":"OG000","title":"aMIL Arm"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"This is an analysis by intention-to-treat and only considers transplanted patients randomized to the aMILs arm.","reportingStatus":"POSTED","timeFrame":"3 years","title":"Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"Participants"}